Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
92.2M
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
2.9M
-
Shares change
-
-644K
-
Total reported value, excl. options
-
$6.3M
-
Value change
-
-$2.23M
-
Number of buys
-
8
-
Number of sells
-
-9
-
Price
-
$2.17
Significant Holders of Context Therapeutics Inc. - Common Stock, par value $0.001 per share (CNTX) as of Q1 2022
19 filings reported holding CNTX - Context Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q1 2022.
Context Therapeutics Inc. - Common Stock, par value $0.001 per share (CNTX) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.9M shares
of 92.2M outstanding shares and own 3.15% of the company stock.
Largest 10 shareholders include SABBY MANAGEMENT, LLC (1.17M shares), Affinity Asset Advisors, LLC (778K shares), Worth Venture Partners, LLC (318K shares), VANGUARD GROUP INC (236K shares), Knoll Capital Management, LLC (140K shares), Veritable, L.P. (110K shares), GEODE CAPITAL MANAGEMENT, LLC (49.9K shares), swisspartners Ltd. (42.2K shares), RENAISSANCE TECHNOLOGIES LLC (20.3K shares), and CITADEL ADVISORS LLC (18.5K shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.